ATR Inhibition Induces CDK1–SPOP Signaling and Enhances Anti–PD-L1 Cytotoxicity in Prostate Cancer

2021139 citationsJournal Articlehybrid Open Access

Authors

Zhe Tang · The University of Texas MD Anderson Cancer Center

Patrick G. Pilié · The University of Texas MD Anderson Cancer Center

Chuandong Geng · The University of Texas MD Anderson Cancer Center

Ganiraju C. Manyam · The University of Texas MD Anderson Cancer Center

Guang Yang · The University of Texas MD Anderson Cancer Center

Sanghee Park · The University of Texas MD Anderson Cancer Center

Abstract

This work provides a molecular mechanistic rationale for combining ATR-targeted agents with immune checkpoint blockade for patients with CRPC. Multiple early-phase clinical trials of this combination are underway.

Topics & Keywords

interferon and immune responses Cancer Immunotherapy and Biomarkers PARP inhibition in cancer therapy

UN Sustainable Development Goals

Good health and well-being

Publication Details

Published in: Clinical Cancer Research

Volume 27, Issue 17, pp. 4898-4909

DOI: 10.1158/1078-0432.ccr-21-1010

Field-Weighted Citation Impact: 8.10